Smartlens, an ophthalmology technology company, has successfully closed a Series A equity financing round to pursue regulatory clearance for its innovative offering miLens; an electronics-free soft contact lens that utilizes microfluidics technology to monitor diurnal intraocular pressure.

Fluctuations in intraocular pressure can indicate the risk factors associated with glaucoma or the progression of the disease. By gathering data using miLens, healthcare providers can gain valuable insights for glaucoma treatment. The technology has the potential to revolutionize glaucoma treatment by allowing physicians to better understand the daily fluctuations in intraocular pressure and mitigate the risk of permanent vision loss.

The funding was led by Ambit Health Ventures, with participation from Stanford University, Sophia Innovation Capital, Graphene Ventures, and others.

Article written by Jessica Hagen



Mobi Health News